Login
$BIOA
$5.21 -$0.01 (0.19%) After hours

$BIOA 8-K SEC Filings

Filed On Filing
05 Nov 2026 8-K: Results of Operations and Financial Condition

First participant dosed in QUELL-DME, a Phase 2 trial of BGE-102, a potential best-in-class oral NLRP3 inhibitor, in diabetic macular edema; topline results anticipated in the second half of 2027

02 Oct 2026 8-K: Other Events

BioAge Labs, Inc. (the “Company”) recently announced that the first participant has been dosed in QUELL-DME, a randomized, controlled Phase 2 trial evaluating once-daily oral BGE-102, an NLRP3 inhibitor, in adults with diabetic macular e...

05 Aug 2026 8-K: Results of Operations and Financial Condition

First participant dosed in QUELL-CV, a Phase 2 dose-ranging proof-of-concept trial of BGE-102 measuring inflammatory and cardiometabolic biomarkers; topline data anticipated in the second half of 2026

12 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 10, 2026, BioAge Labs, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders and the Company’s stockholders voted on and approved the following proposals:

08 May 2026 8-K: Results of Operations and Financial Condition

Positive topline Phase 1 data for BGE-102, demonstrating potential best-in-class reductions among oral NLRP3 inhibitors in inflammatory biomarkers of cardiovascular risk

24 Mar 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Positive interim Phase 1 data for BGE-102, a potent, structurally novel, orally available, brain-penetrant small-molecule NLRP3 inhibitor, demonstrating potential best-in-class reductions in inflammatory biomarkers of cardiovascular risk...

22 Jan 2026 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

As representatives (the “Representatives”) of the several Underwriters

20 Jan 2026 8-K: Regulation FD Disclosure; Other Events

BioAge announces indication expansion for oral NLRP3 inhibitor BGE-102, with plans to initiate Phase 1b/2a proof-of-concept clinical trial in patients with diabetic macular edema in mid-2026

12 Jan 2026 8-K: Regulation FD Disclosure; Other Events

BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk

04 Dec 2025 8-K: Regulation FD Disclosure; Other Events

BGE-102 was well-tolerated in SAD and initial MAD cohorts, with a pharmacokinetic profile supporting once-daily oral dosing

06 Nov 2025 8-K: Results of Operations and Financial Condition

First participant dosed in Phase 1 trial of BGE-102, oral CNS-penetrant NLRP3 inhibitor, with initial SAD data expected by year-end

06 Aug 2025 8-K: Results of Operations and Financial Condition

Oral NLRP3 inhibitor BGE-102 on track for Phase 1 initiation in 2H 2025 with initial data by year-end

09 Jun 2025 8-K: Submission of Matters to a Vote of Security Holders

On June 5, 2025, BioAge Labs, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders and the Company’s stockholders voted on and approved the following proposals:

04 Jun 2025 8-K: Other Events

On June 4, 2025, the Company announced, in its corporate presentation, updates related to anticipated timing of certain milestones, including the following:

06 May 2025 8-K: Results of Operations and Financial Condition

Advancement of lead candidate BGE-102, an oral, brain-penetrant NLRP3 inhibitor for obesity, with initial clinical data expected 2H25

20 Mar 2025 8-K: Results of Operations and Financial Condition

Advancement of oral, brain-penetrant NLRP3 inhibitor BGE-102, with initial clinical data expected 2H25

07 Nov 2024 8-K: Results of Operations and Financial Condition

Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesity

27 Sep 2024 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities

This SHARE PURCHASE AGREEMENT (this “Agreement”) is entered into as of September 25, 2024 (the “Effective Date”), by and between Sofinnova Venture Partners XI, L.P. (the “Investor”), and BioAge Labs, Inc., a Delaware corporation (the “Co...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support